Johnson & Johnson and Proctor & Gamble Companies

Johnson & Johnson Companies Biotech, one of the Johnson & Johnson Companies, has been very concerned with the FDA. The FDA has started to quail at very strict on what drugs they let in the barter; since, the incidents with other well known drugs such as Phen-fen and Lotronex were pulled from the securities application for safety concerns. They have started to get gun-shy with putting other drugs on the market. The FDA will be a big future claim exception for the medical companies incorporated with Johnson & Johnson Companies. Biotech suffered when the FDA made them do more clinical studies on the solelyergy drug, Soltara, which was their biggest drug to come bring out this year. Studies recognized that a condition called QT Prolongation, which can gunpoint teacher to irregular heart beat, is common in antihistamines. In departed studies that were done, they discovered that 2 of the 3 concerns from the FDA were present, but there were no signs of QT prolo ngation. Johnson & Johnson (JNJ.N) and its smaller partner Alkermes Inc. (ALKS.O) said in earlyish July the FDA rejected their request to market an inject open meter reading of J&Js lucrative schizophrenia treatment Risperdal, send Alkermes stock plunging 68 percent.

An analyst identify at the cartridge holder cited an increased risk of pubic louse found in scrutiny of the drug in rodents -- all the same though the drug survived triplet phases of clinical trials in military man without raising a of import cancer concern. This was a major(ip) set back for the caller-up as well as a future challen ge. It may be years onwards they can finis! h all of the studies and put the drug on the market. The FDA has even requested drugs be tested that have been exhaustively tested already, if they are in any category that has experience problems. This creates money problems in most... If you need to get a honorable essay, order it on our website: BestEssayCheap.com

If you want to get a full essay, visit our page: cheap essay